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Abstract
Background: Preoperative screening for nasal S. aureus carriage, followed by eradication treatment of identified carriers
with nasal mupirocine ointment and chlorhexidine soap was highly effective in preventing deep-seated S. aureus infections.
It is unknown how cost-effectiveness of this intervention is affected by suboptimal S. aureus screening. We determined cost-
effectiveness of different preoperative S. aureus screening regimes.
Methods: We compared different screening scenarios (ranging from treating all patients without screening to treating only
identified S. aureus carriers) to the base case scenario without any screening and treatment. Screening and treatment costs
as well as costs and mortality due to deep-seated S. aureus infection were derived from hospital databases and
prospectively collected data, respectively.
Results: As compared to the base case scenario, all scenarios are associated with improved health care outcomes at reduced
costs. Treating all patients without screening is most cost-beneficial, saving J7339 per life year gained, as compared to
J3330 when only identified carriers are treated. In sensitivity analysis, outcomes are susceptible to the sensitivity of the
screening test and the efficacy of treatment. Reductions in these parameters would reduce the cost-effectiveness of
scenarios in which treatment is based on screening. When only identified S. aureus carriers are treated costs of screening
should be less than J6.23 to become the dominant strategy.
Conclusions: Preoperative screening and eradication of S. aureus carriage to prevent deep-seated S. aureus infections saves
both life years and medical costs at the same time, although treating all patients without screening is the dominant
strategy, resulting in most health gains and largest savings.
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Introduction
Deep surgical site infections caused by Staphylococcus aureus are an
important complication of surgical procedures, associated with
increased morbidity and mortality and considerable incremental
health care costs. It is estimated that around 80% of such
infections are caused by strains already colonizing the patient at
the time of surgery, most notably in the anterior nares [1]. In a
multi-centre double-blind placebo-controlled trial, preoperative
screening for nasal S. aureus carriage, followed by S. aureus
eradication treatment of identified carriers with nasal mupirocine
ointment and chlorhexidine gluconate soap, all within one week
before surgery, was associated with 79% and 55% reductions in
deep-seated and superficial S. aureus infections, respectively [2].
Yet, screening all patients preoperatively with PCR-based rapid
diagnostic tests and providing timely treatment to identified
carriers will be an enormous logistical – and costly – challenge.
The cost-effectiveness of this intervention has not been determined
and it is unknown how this will be affected by suboptimal
screening. The aim of this study was, therefore, to quantify costs
and effects of this intervention using different screening scenarios.
Methods
We performed a cost-effectiveness analysis from the societal
perspective and restricted our analyses to deep-seated prosthetic joint
and deep-seated cardio surgical infections (such as mediastinitis), as the
intervention is most relevant for these types of infections. Cost and
mortality related to deep surgical site infections were derived from the
hospital databases of the UMC Utrecht, one of the participating
centres of the recently published multi-centre trial. The UMC Utrecht
is a tertiary medical centre with 1012 beds, in which around 200
prosthetic joint implantations and 1,000 cardiopulmonary surgical
procedures are performed annually. Infectious complications of these
interventions, as well as all costs associated, have been prospectively
monitored from 2001 on by the department of hospital hygiene and
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readmitted because of a postoperative surgical site infection, which
included the number of hospital admission days, surgical procedures,
and diagnostic procedures (mainly radiological and microbiological)
(Table 1). We intentionally restricted cost estimates to the costs
associated with readmission for deep surgical infections in order to not
to include other non-associated costs. Although we might have missed
episodes that were readmitted to other hospitals, we believe this
number to be low and such cases were unlikely to influence the
calculated cost per episode. We assessed hospital mortality of patients
with deep-seated S. aureus prosthetic joint and cardio surgical infections
and quantified the average number of expected life years at the time of
death using life tables from Statistics Netherlands (Table 2). We did
n o ta d j u s tl i f ee x p e c t a n c yf o rc o m o r b i dities. Therefore, life expectan-
cies are overestimated, which implies that the calculated savings per
life year are rather conservative. Institutional review board approval
was not required as monitoring postoperative and other hospital
associated infections is part of the regular infection control program
conducted by the department of hospital hygiene and infection
control.
Parameters used in the model are listed in Table 3. The
incidence of deep-seated S. aureus infections in S. aureus carriers was
4.4% and was assumed to be three to six times lower (1.5% to
0.7%) among non-carriers [3–5]. In order to be conservative in
our estimates of cost-effectiveness, we have used a six times lower
incidence in our calculations. The relative risk of deep-seated S.
aureus infections after mupirocin-chlorhexidine treatment was 0.21
compared to placebo [2]. Sensitivity and specificity of the rapid
diagnostic test was considered 0.97 and 0.99, respectively [2,6].
The calculated costs of the screening strategy included material
and labour costs (real-time PCR assay and conventional culture
costs as determined by the Dutch Healthcare Authority) [7]. We
assumed 5 minutes extra working time for nurses (the average
nurse wage was valued at J26.45 per hour based on gross salary
including taxes and social premiums). Costs of mupirocin ointment
2% and chlorhexidine gluconate soap (40 mg per millilitre) for 5
days were calculated according to the pharmaceutical reference
pricing system [8]. The reference year for cost computations was
2009. Costs related to postoperative surgical site infection have
been adapted to 2009 using the consumer price index as
determined by Statistics Netherlands. Effects (life years gained)
were discounted at 3%, as recommended in the U.S.A. [9]; costs
were not discounted, as all costs are made in one year. Costs were
expressed in Euros (1 Euro =1.43 US dollars, December 2009).
Two scenarios were compared to the base case scenario, in
which none of the patients will be screened or treated for S. aureus
carriage. In scenario 1, it is aimed to screen all patients and only
identified S. aureus carriers receive eradication treatment, as in the
study by Bode et al [2]. Yet, preoperative screening and allocating
treatment within one week before surgery may not be achievable
in all patients, for which estimates of 15% have been reported
[10,11]. Therefore, in scenario 2 not only identified S. aureus
carriers but also patients that could not be screened receive
eradication treatment. In each scenario, proportions of patients
screened were varied from 0% (making scenario 1 identical to base
case, and treating all patients in scenario 2) to 100% (making
scenario 1 and 2 identical). For each of the scenarios total number
of S. aureus infections prevented, costs per infection prevented and
costs per life year gained were determined. In sensitivity analyses,
we explored which uncertain variables in the model were of most
influence on the cost-effectiveness of screening strategies.
Table 1. Direct health care costs of patients readmitted
because of a postoperative surgical site infection between
2001 and 2010.
Department
Cardio
surgical Orthopedic
(n=28) (n=25)
Age, mean 6 SD, years 58 6 16 55 6 15
Male sex (%) 19 (68) 13 (52)
Surgical interventions, no. (%)
coronary artery bypass grafting 20 (71) 0
heart valve replacement 3 (11) 0
total knee or hip prosthesis 0 7 (28)
shoulder surgery 0 3 (12)
spondylodesis 0 3 (12)
other fracture surgery 0 6 (24)
other 5 (18) 6 (24)
Length of hospital stay,
total days (median)
529 (17) 1597 (48)
Total cost of health care, euros (mean/
patient)
surgical procedures 31,605 (1580)
a 71,695 (2987)
b
laboratory investigations 40,149 (1434) 31,781 (1271)
radiological investigations 9068 (363)
c 5071 (211)
b
hospitalization days 150,157 (5363) 499,728 (19,989)
other 3716 (133) 17,705 (708)
total costs readmission
d 234,695 (8382) 625,980 (25,039)
aMissing information on 8 patients.
bMissing information on 1 patient.
cMissing information on 3 patients.
dCosts of antibiotic treatment were not included.
doi:10.1371/journal.pone.0014815.t001
Table 2. Life expectancy of patients with deep-seated
postoperative S. aureus infections.
Characteristic n=37
a
Age, mean 6 SD, years 66 6 17
Male sex (%) 19 (51)
Hospital department (%)
cardio surgical 23 (62)
orthopedic 14 (28)
Postoperative S. aureus infections, no. (%)
mediastinitis 18 (49)
prosthetic joint infection 14 (38)
other deep-seated infection 5 (14)
In-hospital deaths, no. (%) 9 (24)
Expected survival, mean, years
survivors 19.83
survivors, discounted 9.54
non survivors 15.83
non survivors, discounted 9.29
a17 patients (46%) are included in estimate of the cost of a postoperative
surgical site infection.
doi:10.1371/journal.pone.0014815.t002
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Without screening and treatment (base case) there will be 14
deep-seated postoperative S. aureus infections with 3 patients
succumbing from the infection per 1000 procedures, incidence
1.4% (Table 4). Despite large cost differences between scenarios 1
and 2, both scenarios are associated with improved health
outcomes and cost savings, compared to the base case scenario
without screening and treatment (Figure 1). Yet, the scenario with
all patients treated without screening (scenario 2 with 0% of
patients screened) clearly is most cost-effective with highest health
gains (24 discounted life years) and highest cost savings (J178,970)
per 1000 patients. These positive results are explained by the
avoidance of screening costs and from the higher efficacy of the
intervention, as carriers are not missed and non-carriers, though
with a lower infection risk, are also treated.
If test sensitivity of the PCR-based screening test is 65%, as was
reported for the test used in the multi-center trial [6], the
intervention would be less beneficial (and save J930 per life year
gained) in scenario 1 (Figure 2). In scenario 2 (non-screened
patients will all be treated) the effect of test sensitivity on costs per
life year gained decreases with less patients being screened.
We have assumed that the relative risk of deep-seated S. aureus
infections after eradication treatment was 0.21 compared to
placebo. However, if the effect of the intervention is lower, health
outcomes and cost savings are less (Figure 3), and when the relative
risk with eradication is less than, respectively, 0.53 and 0.62 for
scenario 1 and 2, the intervention is no longer cost-saving.
If the proportion of identified S. aureus carriers is higher than
18.5% [1,11], the cost savings will increase for all scenarios. The
largest increase occurs in scenario 1, in which the cost savings per
life year gained will increase from J3330 (with 18.5% carriage) to
J5039 with 30% carriage, which is still lower than the J7339 per
life year gained when all patients are treated without screening.
When only identified S. aureus carriers receive eradication
treatment (scenario 1) costs of screening should be less than J6.23
to become the dominant strategy, resulting in more cost-savings
than scenario 2 with 0% screening. In scenario 2, when all non-
screened patients also receive treatment, the break-even point of the
screening costs will decrease with fewer patients being screened. For
instance, with 85% of patients being screened treating only
identified S. aureus carriers will become the dominant strategy if
the costs of screening become less than J50.27 per patient.
Discussion
Although screening for S. aureus carriage followed by short-term
eradication therapy among identified carriers is associated with
both improved health outcomes and reduced health care costs,
treating all patients without previous screening appears to result in
more infections prevented, more life years gained and higher
Table 3. Parameters used in cost-effectiveness analysis.
Parameter Value Reference
No. of patients colonized with S. aureus, % 18.5 [2]
Incidence of deep-seated S. aureus infections
among S. aureus carriers, %
4.4 [2]
Incidence of deep-seated S. aureus infections
among non-carriers, %
0.7-1.5 [2]
Cost of screening, J 63.90 [7]
Sensitivity of screening test 0.97 [2-5]
Specificity of screening test 0.99 [6]
Cost of treatment, J 15.94 [8]
Relative risk of deep-seated S. aureus infections
due to intervention, %
0.21 [2]
Cost of deep-seated surgical site infection, J 17,820 UMC Utrecht
Hospital mortality among patients with
deep-seated S. aureus infection, %
24 UMC Utrecht
Life expectancy of non-survivors of deep-
seated S. aureus infection, years
15.83 UMC Utrecht
Life expectancy of non-survivors of
deep-seated S. aureus infection, discounted, years
9.29 UMC Utrecht
doi:10.1371/journal.pone.0014815.t003
Table 4. Cost-analysis of different strategies per 1000 patients undergoing prosthetic joint or cardiopulmonary surgery.
Parameter
Base case
Scenario
Scenario 1 (identified
S. aureus carries are
treated: 100%
screened)
Scenario 1
(identified S. aureus
carries are treated:
85% screened)
Scenario 2
(identified S. aureus
carries and non-
screened patients
are treated: 85%
screened)
Scenario 2
(identified S.
aureus carries
and non-
screened
patients are
treated: 0%
screened)
No. of patients screened 0 1000 850 850 0
No. of patients treated 0 185 153 303 1000
No. of deep-seated S. aureus infection 14 7 9 7 3
No. of deaths due to deep-seated S.
aureus infection 3 2 2 2 0.7
No. of life years gained, discounted -31 14 12 15 24
Cost per infection prevented, J NA 10,395 10,703 8518 1457
Cost per life year gained, J 7993 -3330 -3192 -4172 -7339
Total costs saved due to infection
prevention, J -246,722 47,746 37,737 64,583 178,970
doi:10.1371/journal.pone.0014815.t004
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balanced against the risks for selection of mupirocin and/or
chlorhexidine resistance by using these agents in patients not
colonized with S. aureus.
The current analysis was motivated by our own experiences
with implementing preoperative screening for S. aureus carriage in
our hospital. A large - and increasing - number of patients is
admitted just hours before surgery, with the last out-patient clinic
Figure 1. Effect of suboptimal adherence to preoperative S. aureus screening on total costs and life years gained (discounted) per
1000 patients for scenario 1 (only identified S. aureus carriers are treated) and scenario 2 (identified S. aureus carriers and non-
screened patients are treated). Note the negative costs on the y-axis representing cost-savings.
doi:10.1371/journal.pone.0014815.g001
Figure 2. Effect of suboptimal adherence to preoperative S. aureus screening and test sensitivity on cost per life year gained
(discounted) per 1000 patients for differentscreening scenarios. Scenario 1 is treatment of S.aureus carriers identified by screening; scenario 2 is
treatment of S. aureus carriers identified by screening plus treatment of all patients that were not screened. In scenario 1 the life years gained and costs
increase,ordecrease,ataconstantrateresultinginaninvariablecostperlifeyearsgained.Notethenegativecostsonthey-axisrepresentingcost-savings.
doi:10.1371/journal.pone.0014815.g002
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screening and starting treatment is difficult to realize. Further-
more, although the recent clinical trial reported PCR test
sensitivity of 97% [2], the sensitivity as reported in literature is
much lower (65% to 82%) [6,12]. Although negative screening
results have been associated with lower levels of colonization
density [6], possibly reflecting lower infection risks [3,13], patients
potentially benefiting from eradication therapy will be missed in a
screen and treat strategy. These aspects did not affect the multi-
centre trial as only S. aureus carriers, as identified with PCR-testing,
were eligible. Numbers of patients that were not screened were not
available from the Bode publication, but in our hospital we
estimate that more than 50% of the surgical patients were not
screened, due to the before-mentioned reasons. Moreover, the
18.5% incidence of S. aureus carriage in the multi-centre study was
lower than previously estimated, probably because of low test
sensitivity.
Strengths of our analysis include the fact that both costs and
mortality due to deep-seated postoperative S. aureus infections were
based on detailed prospectively determined data. Yet, we still had
to make assumptions on several parameter values, which deserve
comments. For instance, the S. aureus infection rate among non-
carriers was estimated to be three to six times lower than among
carriers based on published data [2,5]. We have used a six times
lower incidence in our calculations, which is a conservative
estimate as a higher incidence of infection would result in
increased savings. Also, the intervention was considered equally
effective in S. aureus carriers and non-carriers. Since the
overwhelming majority of S. aureus infections are from endogenous
origin, this assumption seems not unlikely. Yet, a lower efficacy of
treatment in non-identified carriers would make any strategy that
includes screening less cost-effective. Furthermore, we assumed
that all patients with deep-seated infections that died in our
hospital (i.e., 24%, all cardiosurgical patients) succumbed because
of the infection. Others though have estimated attributable
mortality due to serious S. aureus infections to range from 7–20%
[14,15]. With lower mortality rates the number of life years gained
would become lower, but the relative differences between the
different scenarios would not change. We also limited our analyses
to deep-seated infections, as we had most accurate cost data for
this category of infection and the effect of the intervention was
most pronounced for these infections in the recently published trial
[2]. Real-life cost-effectiveness is assumed to be more beneficial
than reported in this paper, as we disregard the effects of screen
and treat strategies on superficial infections. Only direct health
care costs were included in our analysis. As the average age of
patients dying from nosocomial S. aureus infections in our hospital
was almost 70, inclusion of indirect costs associated with
productivity losses is not thought to have a large influence on
our estimates.
Widespread use of mupirocine and chlorhexidine might
increase the risk of resistance of S. aureus, as resistance for both
agents has been reported. However, overall resistance rates for
both agents are still low, despite widespread use in the last decades.
Some S. aureus strains carry the plasmid-born qacA/B genes which
code for multidrug efflux pumps and increase minimum
bactericidal concentrations (MBCs) to chlorhexidine [16]. Al-
though presence of these genes have been associated with reduced
efficacy of a chlorhexidine-based decolonization strategy to
prevent MRSA transmission in a British ICU [17], MBCs usually
remain below concentrations to treat patients and the clinical
significance of these qacA/B genes remains unclear [18]. Yet,
whether treatment in the absence of S. aureus colonization increases
the risk of resistance to mupirocine and chlorhexidine (for instance
through selection of plasmid-born resistance in coagulase-negative
staphylococci) is unknown. Yet, based on the cost-effectiveness of
decolonization to prevent deep-seated postoperative S. aureus
infections, we conclude that the benefits of treating non-detected
Figure 3. Effect of suboptimal adherence to preoperative S. aureus screening and treatment effectiveness on cost per life year
gained (discounted) per 1000 patients for different screening scenarios. Scenario 1 is treatment of S. aureus carriers identified by screening;
scenario 2 is treatment of S. aureus carriers identified by screening plus treatment of all patients that were not screened. In scenario 1 the life years
gained and costs increase, or decrease, at a constant rate resulting in an invariable cost per life years gained. Note the negative costs on the y-axis
representing cost-savings.
doi:10.1371/journal.pone.0014815.g003
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effectiveness due to widespread resistance to antiseptics and
mupirocine. Surveillance cultures will be necessary for early
detection of emerging resistance.
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